SCOPUS 정보 검색 플랫폼

Nature Reviews Drug Discovery

Volumn 9, Issue 10, 2010, Pages 759-760

The multiple sclerosis market

(1) Huynh, Trung a

a Datamonitor (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; CLADRIBINE; DACLIZUMAB; EXTAVIA; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GILENIA; GLATIRAMER; HMR 215062; INTERFERON BETA SERINE; LAQUINIMOD; MITOXANTRONE; MOVECTRO; NATALIZUMAB; TERIFLUNOMIDE; UNCLASSIFIED DRUG; BETA INTERFERON; PEPTIDE;

CLINICAL TRIAL; COST CONTROL; DRUG COST; DRUG EFFICACY; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SHORT SURVEY; ANIMAL; DRUG DEVELOPMENT; ECONOMICS; HEALTH CARE COST; TRENDS;

ANIMALS; DRUG DISCOVERY; HEALTH CARE SECTOR; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PEPTIDES;

EID: 77957374582 PISSN: 14741776 EISSN: 14741784 Source Type: Journal
DOI: 10.1038/nrd3272 Document Type: Short Survey

Times cited : (8)

References (8)

1
- 0008376732
- Interferon β in the treatment of multiple sclerosis: Mechanisms of action
- Yong, V. W. et al. Interferon β in the treatment of multiple sclerosis: mechanisms of action. Neurology 51, 682-689 (1998).
- (1998) Neurology , vol.51 , pp. 682-689
- Yong, V.W.¹

2
- 85069123171
- Copaxone. Copaxone prescribing information. Copaxone website [online], http://www.copaxone.com/pdf/PrescribingInformation.pdf (2010).
- (2010) Copaxone. Copaxone Prescribing Information. Copaxone Website [Online]

3
- 35748930835
- National Institute for Health and Clinical Excellence NICE website [online]
- National Institute for Health and Clinical Excellence. Multiple sclerosis-β interferon and glatiramer acetate. NICE website [online], http://www.nice.org.uk/guidance/index.jsp?action=byID&r=true&o=11441 (2002).
- (2002) Multiple Sclerosis-β Interferon and Glatiramer Acetate

4
- 72449125358
- Multiple sclerosis risk sharing scheme: Two year results of clinical cohort study with historical comparator
- Boggild, M. et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ 339, b4677 (2009).
- (2009) BMJ , vol.339
- Boggild, M.¹

5
- 77749326809
- Novartis Novartis website [online]
- Novartis. Two-year Phase III study shows Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression. Novartis website [online], http://www.novartis.com/newsroom/media-releases/en/2009/1344775.shtml (2009).
- (2009) Two-year Phase III Study Shows Novartis Oral MS Therapy FTY720 Significantly Reduces Relapses and Disability Progression

6
- 54949143968
- The CAMMS223 trial investigators. Alemtuzumab vs. interferon β-1a in early multiple sclerosis
- The CAMMS223 trial investigators. Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786-1801 (2008).
- (2008) N. Engl. J. Med. , vol.359 , pp. 1786-1801

7
- 77949301468
- Daclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, doubleblind, placebo-controlled, add-on trial with interferon β
- Wynn, D. et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, doubleblind, placebo-controlled, add-on trial with interferon β. Lancet Neurol. 9, 381-390 (2010).
- (2010) Lancet Neurol. , vol.9 , pp. 381-390
- Wynn, D.¹

8
- 85069123370
- Datamonitor Datamonitor
- Datamonitor. Commercial insight: multiple sclerosis-next generation therapies signal the start of a new era.(Datamonitor, 2010).
- (2010) Commercial Insight: Multiple Sclerosis-next Generation Therapies Signal the Start of A New Era

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.